Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maximum androgen blockade in 1996

L Boccon-Gibod1

  • 1Department of Urology, CHU Bichat, Paris, France.

European Urology
|January 1, 1996
PubMed
Summary

Maximal androgen blockade (MAB) using nonsteroidal antiandrogens shows marginal survival benefits for prostate cancer patients. Further research is needed to identify optimal candidates and address potential androgen receptor mutations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malformations, genetic abnormalities, and Wilms tumor.

Pediatric blood & cancer·2013
Same author

[Prostate cancer, androgenic suppression and associated conditions. Practical refinement by a panel of multidisciplinary experts for patient integral management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2012
Same author

[New perspectives in prostate cancer management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2010
Same author

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

[First line indications for hormonal therapy in prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2010
Same author

[AFU 2008 congress: Summary of the main communications about prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2009

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Maximal androgen blockade (MAB) for prostate cancer treatment remains controversial.
  • Despite extensive trials, uncertainties persist regarding MAB's efficacy and optimal use.
  • Over 5,000 patients with metastatic prostate cancer have participated in MAB trials.

Purpose of the Study:

  • To review the current status of maximal androgen blockade (MAB) in prostate cancer treatment.
  • To evaluate the efficacy and modalities of MAB.
  • To identify patient subgroups who may benefit from MAB.

Main Methods:

  • Review of existing literature and meta-analyses on MAB in prostate cancer.
  • Analysis of clinical trial data concerning MAB efficacy and side effects.
  • Assessment of antiandrogen mechanisms and potential resistance.

Main Results:

  • MAB with steroidal antiandrogens has limited efficacy.
  • Nonsteroidal antiandrogens are preferred for MAB, with no significant differences among flutamide, nilutamide, and bicalutamide.
  • MAB's impact on survival and progression-free survival is marginal, though a trend favors MAB.

Conclusions:

  • MAB efficacy is limited, particularly with steroidal antiandrogens.
  • Nonsteroidal antiandrogens are the preferred agents for MAB.
  • Further research is needed to define MAB's role and identify responsive patient populations.
  • Potential androgen receptor mutations necessitate careful monitoring and consideration of antiandrogen withdrawal.

Related Experiment Videos